- Home
- AMSF vs CSTL Comparison
AMSF vs CSTL Comparison
Compare AMSF & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | CSTL |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 758.5M | 661.7M |
| IPO Year | 2005 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AMSF | CSTL |
|---|---|---|
| Price | $40.07 | $39.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $58.33 | $38.67 |
| AVG Volume (30 Days) | 122.0K | ★ 531.8K |
| Earning Date | 10-29-2025 | 11-03-2025 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.60 | N/A |
| Revenue | $309,746,000.00 | ★ $343,530,000.00 |
| Revenue This Year | $3.54 | N/A |
| Revenue Next Year | $4.84 | N/A |
| P/E Ratio | $15.47 | ★ N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $39.09 | $14.59 |
| 52 Week High | $59.33 | $40.61 |
Technical Indicators
Market Signals| Indicator | AMSF | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.07 | 78.03 |
| Support Level | $40.00 | $38.64 |
| Resistance Level | $41.52 | $40.61 |
| Average True Range (ATR) | 0.84 | 1.45 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 15.63 | 80.79 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.